Medicus Pharma Ltd. — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Medicus Pharma received Nasdaq confirmation (Nov 18, 2026) of regained compliance with the $2.5M minimum shareholders' equity listing requirement. The company raised ~$4.25M in equity ($3.0M registered direct offering + ~$1.25M insider placements including $750K from CEO Dr. Raza Bokhari) and exchanged $10.5M of debt held by Streeterville Capital for non-convertible preferred shares. Compliance is conditional; the company must evidence continued compliance by Dec 31, 2026 or face delisting.
Why this rating
At $28.3M market cap, $14.75M in total capital restructuring (15% dilution + debt conversion) is material. Delisting risk elimination is significant, but conditional compliance and near-term re-testing create ongoing uncertainty.
Tradability signal
NO TRADE
No trade: price $0.20 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.20 | +10 min · unknown $0.20 ▲ 0.00% | +30 min · unknown $0.20 ▲ 0.00% | +1 hr · unknown $0.20 ▲ 0.00% | +4 hrs · unknown $0.20 ▲ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.